Methods and compositions for inhibition of bromodomain-containing proteins
10717739 ยท 2020-07-21
Assignee
Inventors
- Hariprasad Vankayalapati (Draper, UT)
- Makoto YOSHIOKA (Gaithersburg, MD, US)
- Jeffrey William Strovel (Laurel, MD, US)
- Janak Khimchand Padia (Germantown, MD, US)
Cpc classification
A61P1/04
HUMAN NECESSITIES
A61P29/00
HUMAN NECESSITIES
C07D215/227
CHEMISTRY; METALLURGY
C07D413/04
CHEMISTRY; METALLURGY
A61P7/00
HUMAN NECESSITIES
C07D261/08
CHEMISTRY; METALLURGY
A61P43/00
HUMAN NECESSITIES
A61P1/18
HUMAN NECESSITIES
A61P1/16
HUMAN NECESSITIES
A61P35/00
HUMAN NECESSITIES
C07D409/06
CHEMISTRY; METALLURGY
C07C217/84
CHEMISTRY; METALLURGY
C07D405/06
CHEMISTRY; METALLURGY
C07D401/12
CHEMISTRY; METALLURGY
C07D405/04
CHEMISTRY; METALLURGY
A61P25/28
HUMAN NECESSITIES
C07D401/04
CHEMISTRY; METALLURGY
International classification
C07D215/227
CHEMISTRY; METALLURGY
C07D401/04
CHEMISTRY; METALLURGY
C07D401/12
CHEMISTRY; METALLURGY
C07D261/08
CHEMISTRY; METALLURGY
C07C217/84
CHEMISTRY; METALLURGY
C07D409/06
CHEMISTRY; METALLURGY
C07D405/06
CHEMISTRY; METALLURGY
C07D405/04
CHEMISTRY; METALLURGY
C07D413/04
CHEMISTRY; METALLURGY
Abstract
The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.
Claims
1. A method of treating a disease or condition responsive to the inhibition of binding between bromodomain-containing proteins and acetylated proteins selected from human NUT midline carcinoma, multiple myeloma, lymphoma, leukemia, Burkitt's lymphoma, myeloid leukemia, T-cell lymphoblastic leukemia, hemotological cancer involving translocations of mixed-lineage leukemia gene (MLL), hepatocellular carcinoma, glioblastoma, neuroblastoma, sarcoma, breast cancer, colorectal cancer, lung cancer, pancreatic cancer, prostate cancer, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, and HIV infection, the method comprising administering a therapeutically effective amount of a compound selected from: 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)-1-methylquinolin-2(1H)-one; and 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
2. The method of claim 1, wherein the compound is 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)-1-methylquinolin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein the compound is 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1, wherein the disease or condition is pancreatic cancer.
5. The method of claim 1, wherein the disease or condition is sarcoma.
6. The method of claim 1, wherein the disease or condition is breast cancer.
7. The method of claim 1, wherein the disease or condition is prostate cancer.
8. A method of treating acute myeloid leukemia, comprising administering a therapeutically effective amount of a compound selected from: 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)-1-methylquinolin-2(1H)-one; and 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
9. The method of claim 8, wherein the compound is 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)-1-methylquinolin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
10. The method of claim 8, wherein the compound is 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
11. A method of treating a disease or condition selected from fibrosis and inflammation in a patient in need thereof, comprising administering a compound selected from: 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)-1-methylquinolin-2(1H)-one; and 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
12. The method of claim 11, wherein the compound is 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)-1-methylquinolin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
13. The method of claim 11, wherein the compound is 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
14. The method of claim 11, wherein the disease or condition is fibrosis.
15. The method of claim 14, wherein the fibrosis is idiopathic pulmonary fibrosis.
16. The method of claim 11, wherein the disease or condition is inflammation.
17. The method of claim 16, wherein the inflammation is associated with an inflammatory disease or condition selected from rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis, alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, atherosclerosis, depression, retinitis, uveitis, scleritis, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes, and acute rejection of transplanted organ.
18. The method of claim 16, wherein the inflammation is associated with an inflammatory disease or condition selected from acute gout, giant cell arteritis, nephritis, vasculitis, glomerulonephritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, and Takayasu's Arteritis.
19. The method of claim 16, wherein the inflammation is associated with sepsis, septic shock, endotoxaemia, systemic inflammatory response syndrome, multiorgan dysfunction syndrome, toxic shock syndrome, acute lung injury, adult respiratory distress syndrome, acute renal failure, fulminant hepatitis, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria, and SIRS associated with influenza, herpes zoster, herpes simplex, or coronavirus.
Description
DETAILED DESCRIPTION OF THE INVENTION
(1) The scope of the present invention includes all combinations of aspects and embodiments.
(2) The following definitions are meant to clarify, but not limit, the terms defined. If a particular term used herein is not specifically defined, such term should not be considered indefinite. Rather, terms are used within their accepted meanings.
(3) As used throughout this specification, the preferred number of atoms, such as carbon atoms, will be represented by, for example, the phrase C.sub.x-C.sub.y alkyl, which refers to an alkyl group, as herein defined, containing the specified number of carbon atoms. Similar terminology will apply for other preferred terms and ranges as well. Thus, for example, C.sub.1-6 alkyl represents a straight or branched chain hydrocarbon containing one to six carbon atoms.
(4) As used herein the term alkyl refers to a straight or branched chain hydrocarbon, which may be optionally substituted, with multiple degrees of substitution being allowed. Examples of alkyl as used herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, tert-butyl, isopentyl, and n-pentyl.
(5) As used herein, the term alkene refers to an unsaturated hydrocarbon that includes one or more carbon-carbon double bonds. The term lower alkene refers to an alkene that includes from five to twenty carbon atoms, such as from two to ten carbon atoms, while the term upper alkene refers to an alkene that includes more than twenty carbon atoms, such as from twenty-one to one hundred carbon atoms. The term substituted alkene refers to an alkene that has one or more of its hydrogen atoms replaced by one or more substituent groups, such as halogen.
(6) As used herein, the term alkyne refers to an unsaturated hydrocarbon that includes one or more carbon-carbon triple bonds. The term lower alkyne refers to an alkyne that includes from five to twenty carbon atoms, such as from two to ten carbon atoms, while the term upper alkyne refers to an alkyne that includes more than twenty carbon atoms, such as from twenty-one to one hundred carbon atoms. The term substituted alkyne refers to an alkyne that has one or more of its hydrogen atoms replaced by one or more substituent groups, such as halogen.
(7) As used herein, the term cycloalkyl refers to a fully saturated optionally substituted monocyclic, bicyclic, or bridged hydrocarbon ring, with multiple degrees of substitution being allowed. Preferably, the ring is three to twelve-membered, more preferably, from five- to six-membered. Exemplary cycloalkyl groups as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
(8) As used herein, the term alkoxy refers to a group OR.sup.a, where R.sup.a is alkyl as defined herein.
(9) As used herein, the term heterocycloalkyl or heterocycle or heterocyclyl refers to an optionally substituted mono- or polycyclic ring system, optionally containing one or more degrees of unsaturation, and also containing one or more heteroatoms, which may be optionally substituted, with multiple degrees of substitution being allowed. Exemplary heteroatoms include nitrogen, oxygen, or sulfur atoms, including N-oxides, sulfur oxides, and dioxides. Preferably, the ring is three to twelve-membered, preferably five or six-membered and is either fully saturated or has one or more degrees of unsaturation. Such rings may be optionally fused to one or more of another heterocyclic ring(s) or cycloalkyl ring(s). Examples of heterocyclic groups as used herein include, but are not limited to, tetrahydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane, piperidine, pyrrolidine, morpholine, tetrahydrothiopyran, and tetrahydrothiophene.
(10) As used herein, the term aryl refers to a single benzene ring or fused benzene ring system which may be optionally substituted, with multiple degrees of substitution being allowed. Examples of aryl groups as used include, but are not limited to, phenyl, 2-naphthyl, 1-naphthyl, anthracene, and phenanthrene. Preferable aryl rings have five- to ten-members. The term aryl also includes a fused benzene ring system, namely where a cyclic hydrocarbon or heterocycle (e.g., a cyclohexane or dioxane ring) or heteroaryl (e.g., pyridine) is fused with an aromatic ring (aryl, such as a benzene ring).
(11) As used herein, the term heteroaryl refers to a monocyclic five to seven membered aromatic ring, a fused bicyclic aromatic ring system comprising two of such aromatic rings, which may be optionally substituted, with multiple degrees of substitution being allowed, or to a fused bicyclic ring system namely where a cycloalkyl or heterocycle (e.g., a cyclohexane or dioxane ring) is fused with a heteroaryl ring. Preferably, heteroaryl rings contain five- to ten-members. These heteroaryl rings contain one or more nitrogen, sulfur, and/or oxygen atoms. In certain embodiments, the heteroaryl rings contain one to three nitrogen, one to three oxygen, and one or two sulfur atoms. N-oxides, sulfur oxides, and dioxides are permissible heteroatom substitutions. Examples of heteroaryl groups as used herein include, but are not limited to, furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, quinoxaline, benzofuran, benzoxazole, benzothiophene, indole, indazole, benzimidazole, imidazopyridine, pyrazolopyridine, and pyrazolopyrimidine.
(12) As used herein the term halogen refers to fluorine, chlorine, bromine, or iodine.
(13) As used herein the term haloalkyl refers to an alkyl group, as defined herein, that is substituted with at least one halogen. Examples of branched or straight chained haloalkyl groups as used herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, and t-butyl substituted independently with one or more halogens, for example, fluoro, chloro, bromo, and iodo. The term haloalkyl should be interpreted to include such substituents as perfluoroalkyl groups such as CF.sub.3.
(14) As used herein, the term sulfhydryl refers to refers to a SH group.
(15) As used herein, the term carboxyamido refers to NHC(O)W, wherein W is hydrogen or an unsubstituted or substituted alkyl, alkene, alkyne, cycloalkyl, aryl, or heterocycle group.
(16) As used herein, the term amine is given its ordinary meaning and includes primary, secondary and tertiary amines.
(17) As used herein, the term amido refers to a group of the formula C(O)NR.sup.15R.sup.16, wherein R.sup.15 and R.sup.16 are alkyl, cycloalkyl or heterocycle, or R.sup.15 and R.sup.16 can form cycloalkyl or heterocycle. As used herein, the term sulfamido refers to the group SO.sub.2NR.sup.5R.sub.6.
(18) As used herein, the term pharmaceutically acceptable refers to carrier(s), diluent(s), excipient(s) or salt forms of the compounds of the present invention that are compatible with the other ingredients of the formulation and not deleterious to the recipient of the pharmaceutical composition.
(19) As used herein, the term pharmaceutical composition refers to a compound of the present invention optionally admixed with one or more pharmaceutically acceptable carriers, diluents, or excipients. Pharmaceutical compositions preferably exhibit a degree of stability to environmental conditions so as to make them suitable for manufacturing and commercialization purposes.
(20) As used herein, the terms effective amount, therapeutic amount, and effective dose refer to an amount of the compound of the present invention sufficient to elicit the desired pharmacological or therapeutic effects, thus resulting in an effective treatment of a disorder. Treatment of a disorder may be manifested by delaying or preventing the onset or progression of the disorder, as well as the onset or progression of symptoms associated with the disorder. Treatment of a disorder may also be manifested by a decrease or elimination of symptoms, reversal of the progression of the disorder, as well as any other contribution to the well being of the patient. The effective dose can vary, depending upon factors such as the condition of the patient, the severity of the symptoms of the disorder, and the manner in which the pharmaceutical composition is administered. Effective doses may be administered as a single dose, or as one or more doses that may be administered over a 24 hours period.
(21) According to one embodiment, the compound is at least one compound selected from Formula I, Formula 1A, Formula 1B, Formula 1C or Formula 1D as provided herein, including those compounds set forth in Tables 1-6 and 10.
(22) According to one embodiment, the compound is at least one compound selected from: 6-chloro-3-cinnamoyl-4-phenylquinolin-2(1H)-one; 6-chloro-3-(3-(2-chloro-6-fluorophenyl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-chloro-3-(3-(2,4-dichlorophenyl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-chloro-4-phenyl-3-(3-o-tolylacryloyl)quinolin-2(1H)-one; 6-chloro-3-(3-(2-methoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-chloro-3-(3-(3,4-dimethoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-chloro-4-phenyl-3-(3-(thiophen-2-yl)acryloyl)quinolin-2(1H)-one; 6-chloro-3-(3-(4-(dimethylamino)phenyl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-bromo-3-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-bromo-3-(3-(2,5-dimethoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-chloro-3-cinnamoyl-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-4-(pyridin-3-yl)-3-(3-o-tolylacryloyl)quinolin-2(1H)-one; 6-chloro-N-(2-methylbenzyl)-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxamide; 6-chloro-3-cinnamoyl-4-phenyl-1,8-naphthyridin-2(1H)-one; 6-chloro-3-(3-(2-chloro-6-fluorophenyl)acryloyl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(3-(3-fluoro-5-methylpyridin-4-yl)acryoyl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-chloro-3-cinnamoyl-N-(3-methoxyphenyl)-2-oxo-1,2-dihydroquinoline-4-sulfonamide; 6-chloro-3-cinnamoyl-2-oxo-N-(pyridin-3-yl)-1,2-dihydroquinoline-4-sulfonamide; 6-chloro-3-(3-(2-chloro-6-fluorophenyl)but-2-enoyl)-4-phenylquinolin-2(1H)-one; 3-cinnamoyl-6-(3,5-dimethylisoxazol-4-yl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-(piperidin-1-yl)quinolin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-(pyrrolidin-1-yl)quinolin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-morpholinoquinolin-2(1H)-one; 5-(2-chlorovinyl)-4-(4-ethylpiperazin-1-yl)-3-(2-methyloxazol-4-yl)-6-vinyl pyridin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-(1H-pyrrol-1-yl)quinolin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-(1H-pyrazol-1-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(pyrrolidin-1-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-1-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-morpholinoquinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(4-methyl piperazin-1-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazo-4-yl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(pyridin-2-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(1H-pyrrol-1-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(furan-3-yl)quinolin-2(1H)-one; 6-chloro-3-(3,5-dimethylisoxazol-4-yl)-4-(isoxazol-4-yl)quinolin-2(1H)-one; 6-chloro-3-(isoxazol-4-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(1H-pyrazol-4-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(furan-3-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-4-(pyridin-4-yl)-3-(thiophen-3-yl)quinolin-2(1H)-one; 6-chloro-3-(1H-imidazol-4-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-(3,5-dimethylisoxazo-4-yl)-3-(morpholinosulfonyl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-(3,5-di methylisoxazol-4-yl)-3-(4-methyl piperazin-1-ylsulfonyl)-4-(pyridin-3-yl)quinolin-2(1H)-one; N-(3-cinnamoyl-2-oxo-4-(pyridin-3-yl)-1,2-dihydroquinolin-6-yl)-5-methylisoxazole-3-carboxamide; 6-(3,5-dimethylisoxazol-4-yl)-3-(morpholinosulfonyl)quinolin-2(1H)-one; 6-(3,5-dimethylisoxazol-4-yl)-3-(4-methylpiperazin-1-ylsulfonyl)quinolin-2(1H)-one; 4-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2-dihydroquinolin-3-yl)-N-ethyl-N-methylbenzamide; 6-(3,5-dimethylisoxazol-4-yl)-3(2-fluoro-5-(morpholine-4-carbonyl)phenyl)quinolin-2(1H)-one; N-cyclopentyl-3-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2-dihydroquinolin-3-yl)benzenesulfonamide; 3-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2-dihydroquinolin-3-yl)-N,N-dimethylbenzenesulfonamide; 3-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2-dihydroquinolin-3-yl)-N-(1-methylpyrrolidin-3-yl)benzenesulfonamide; 3-(1H-benzo[d]imidazole-2-carbonyl)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 5-(3,5-dimethylisoxazol-4-yl)-3-(2-(pyridin-3-yl)ethyl idene)indolin-2-one; 6-(3,5-dimethylisoxazol-4-yl)-1-(pyridin-3-ylmethyl)-1H-benzo[d]imidazol-2(3H)-one; 6-(3-chloroisoxazol-5-yl)-3-(morpholinosulfonyl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 3-(3,5-dimethylisoxazol-4-yl)-6-(morpholinosulfonyl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-(3-chloroisoxazol-5-yl)-3-cinnamoyl-4-phenylquinolin-2(1H)-one; (E)-methyl 5-(3-cinnamoyl-2-oxo-4-(pyridin-3-yl)-1,2-dihydroquinolin-6-yl)-2-methyloxazole-4-carboxylate; 6-(3-chloroisoxazol-5-yl)-3-cinnamoyl-4-(pyridin-3-yl)quinolin-2(1H)-one; 3-cinnamoyl-6-(3,5-dimethylisoxazol-4-yl)-4-(phenylamino)quinolin-2(1H)-one; 3-cinnamoyl-6-(3,5-dimethylisoxazol-4-yl)-4-(pyridin-3-ylamino)quinolin-2(1H)-one; N-(3-benzoyl-2-oxo-1,2-dihydroquinolin-5-yl)-2-methoxybenzenesulfonamide; N-(3-cinnamoyl-2-oxo-1,2-dihydroquinolin-5-yl)pyridine-3-sulfonamide; N-(3-benzoyl-2-oxo-1,2-dihydroquinolin-5-yl)pyridine-3-sulfonamide; N-(3-cinnamoyl-2-oxo-1,2-dihydroquinolin-5-yl)-2-methoxybenzenesulfonamide; 6-(3,5-dimethylisoxazo-4-yl)-3-(morpholine-4-carbonyl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-chloro-3-(3-chloroisoxazol-5-yl)quinolin-2(1H)-one; N-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)-5-methylisoxazole-3-carboxamide; 6-(3,5-dimethylisoxazol-4-yl)-3-(morpholine-4-carbonyl)quinolin-2(1H)-one; 6-chloro-4-(4-(2-fluorophenyl)piperazin-1-yl)-3-(2-methyloxazol-4-yl)quinolin-2(1H)-one; 6-chloro-4-(4-(3-fluorophenyl)piperazin-1-yl)-3-(2-methyloxazol-4-yl)quinolin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-(4-(pyridin-2-yl)piperazin-1-yl)quinolin-2(1H)-one; 6-chloro-3-(2-methyloxazol-4-yl)-4-(4-phenethylpiperazin-1-yl)quinolin-2(1H)-one; 3-bromo-6-chloro-4-hydroxy-1-(4-methoxybenzyl)quinolin-2(1H)-one; 6-chloro-1H-benzo[d][1,3]oxazine-2,4-dione; 1-benzyl-6-chloro-1H-benzo[d][1,3]oxazine-2,4-dione; 6-chloro-1-(4-methoxybenzyl)-1H-benzo[d][1,3]oxazine-2,4-dione; 1-benzyl-6-chloro-3-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl trifluoromethanesulfonate; 3-acetyl-6-bromo-4-phenylquinolin-2(1H)-one; 6-bromo-3-cinnamoyl-4-phenylquinolin-2(1H)-one; 6-chloro-4-hydroxy-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)quinolin-2(1H)-one; 6-chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl 4-methylbenzenesulfonate; -chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl benzenesulfonate; 6-chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl 4-fluorobenzenesulfonate; 6-chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl 4-chlorobenzenesulfonate; 6-chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl naphthalene-2-sulfonate; 6-chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl quinoline-8-sulfonate; 6-chloro-1-(4-methoxybenzyl)-3-(2-methyloxazol-4-yl)-2-oxo-1,2-dihydroquinolin-4-yl biphenyl-4-sulfonate; N-(4-(2-chlorovinyl)-6-(3,5-dimethylisoxazol-4-yl)-5-hydroxyhexa-1,5-dien-3-yl)-N-(hepta-2,4,6-trienyl)formamide; N1,N3-bis(4-bromophenyl)malonamide; N1,N3-bis(4-(3,5-dimethylisoxazol-4-yl)phenyl)malonamide; 6-(3,5-dimethylisoxazol-4-yl)-4-hydroxyquinolin-2(1H)-one; 4-chloro-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 4-(2-chlorobenzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 6-(3,5-dimethylisoxazol-4-yl)-4-morpholinoquinolin-2(1H)-one; 6-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-1-yl)quinolin-2(1H)-one; 4-(benzylamino)-1-(benzylsulfonyl)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; and salts thereof.
(23) The compounds of the present invention may crystallize in more than one form, a characteristic known as polymorphism, and such polymorphic forms (polymorphs) are within the scope of the present invention. Polymorphism generally can occur as a response to changes in temperature, pressure, or both. Polymorphism can also result from variations in the crystallization process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility, and melting point.
(24) Certain of the compounds described herein contain one or more chiral centers, or may otherwise be capable of existing as multiple stereoisomers. The scope of the present invention includes mixtures of stereoisomers as well as purified enantiomers or enantiomerically/diastereomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by the formulae of the present invention, as well as any wholly or partially equilibrated mixtures thereof. The present invention also includes the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted.
(25) The present invention includes a salt or solvate of the compounds herein described, including combinations thereof such as a solvate of a salt. The compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms, and the present invention encompasses all such forms. The salts of the present invention can be pharmaceutically acceptable salts which includes non-toxic salts of the compounds set forth herein.
(26) Examples of suitable pharmaceutically acceptable salts include inorganic acid addition salts such as chloride, bromide, sulfate, phosphate, and nitrate; organic acid addition salts such as acetate, galactarate, propionate, succinate, lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, and ascorbate; salts with acidic amino acid such as aspartate and glutamate; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; ammonium salt; organic basic salts such as trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, and N,N-dibenzylethylenediamine salt; and salts with basic amino acid such as lysine salt and arginine salt. The salts may be in some cases hydrates or ethanol solvates.
(27) Although it is possible to administer the compound of the present invention in the form of a bulk active chemical, it is preferred to administer the compound in the form of a pharmaceutical composition or formulation. Thus, pharmaceutical compositions are provided that include one or more compounds of Formula I and/or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers, diluents, or excipients. Another aspect of the invention provides a process for the preparation of a pharmaceutical composition including admixing one or more compounds of Formula I and/or pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable carriers, diluents or excipients.
(28) The manner in which the compounds set forth herein may be administered can vary. According to one embodiment, the compounds can be administered orally. Preferred pharmaceutical compositions may be formulated for oral administration in the form of tablets, capsules, caplets, syrups, solutions, and suspensions. Such oral formulations can be provided in modified release dosage forms such as time-release tablet and capsule formulations. Pharmaceutical compositions can also be administered via injection, namely, intravenously, intramuscularly, subcutaneously, intraperitoneally, intraarterially, intrathecally, and intracerebroventricularly. Intravenous administration is a preferred method of injection. Suitable carriers for injection are well known to those of skill in the art and include 5% dextrose solutions, saline, and phosphate buffered saline.
(29) Pharmaceutical compositions may also be administered using other means, for example, rectal administration. Formulations useful for rectal administration, such as suppositories, are well known to those of skill in the art. The compounds can also be administered by inhalation, for example, in the form of an aerosol; topically, such as, in lotion form; transdermally, such as, using a transdermal patch (for example, by using technology that is commercially available from Novartis and Alza Corporation); by powder injection; or by buccal, sublingual, or intranasal absorption. Pharmaceutical compositions may be formulated in unit dose form, or in multiple or subunit doses.
(30) The administration of the pharmaceutical compositions described herein can be intermittent, or at a gradual, continuous, constant or controlled rate. The pharmaceutical compositions may be administered to a warm-blooded animal, for example, a mammal such as a human being. In addition, the time of day and the number of times per day that the pharmaceutical composition is administered can vary.
(31) The compounds as provided herein may also be used for the preparation of a medicament for the treatment or prevention of a disease or condition mediated by inhibiting bromodomain-containing proteins from binding acetylated proteins.
(32) Methods for treating, preventing, delaying the onset of, or slowing the progression of disorders mediated by acetylated proteins involved in the regulation of gene expression, in mammals in need of such treatment are also provided. The methods involve administering to a subject a therapeutically effective amount of a compound as provided herein, including a salt thereof, or a pharmaceutical composition that includes such compounds.
(33) According to one embodiment, the methods include the administration of at least one compound provided in Tables 1-6 and 10. According to another embodiment, the methods include the administration of at least one of the following compounds: 6-bromo-4-phenyl-3-(6-phenyl-2-thioxo-1,2-dihydropyrimidin-4-yl)quinolin-2(1H)-one; 6-chloro-4-phenyl-3-(6-phenyl-2-thioxo-1,2-dihydropyrimidin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(6-(pyridin-4-yl)-2-thioxo-1,2-dihydropyrimidin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(6-phenyl-2-thioxo-1,2-dihydropyrimidin-4-yl)-4-(pyridin-3-yl)quinolin-2(1H)-one; 6-chloro-3,4-di(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(pyridin-3-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(pyridin-2-yl)-4-(pyridin-4-yl)quinolin-2(1H)-one; 6-chloro-3-(5-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)pyridin-1-yl)quinolin-2(1H)-one; 2,5-dimethoxy-N-((2-methoxynaphthalen-1-yl)methyl)aniline; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinol in-3-yl)propionamide; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)acetamide; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)benzamide; 3-(1H-benzo[d]imidazol-2-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; 3-(4H-1,2,4-triazol-3-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; 6-chloro-4-phenyl-3-(tosylmethyl)quinolin-2(1H)-one; 3-(4-allyl-5-(thiophen-2-yl)-4H-1,2,4-triazol-3-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; 6-chloro-3-(4-(4-methoxyphenyl)-6-oxo-1,6-dihydropyrimidin-2-ylthio)-4-phenylquinolin-2(1H)-one; 4-phenyl-3-(pyridin-2-ylthio)quinolin-2(1H)-one; 3-(4-amino-6-oxo-1,6-dihydropyrimidin-2-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; 4-(2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one; 3-(4-ethyl-5-(morpholinomethyl)-4H-1,2,4-triazol-3-ylthio)-4-phenylquinolin-2(1H)-one; 6-chloro-4-phenylquinolin-2(1H)-one; 6-bromo-3-(5-(4-methoxyphenyl)-4,5-dihydroisoxazol-3-yl)-4-phenylquinolin-2(1H)-one; 6-chloro-3-(5-methoxy-1H-benzo[d]imidazol-2-ylthio)-4-phenylquinolin-2(1H)-one; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-2-chlorobenzamide; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-3-chlorobenzamide; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)benzenesulfonamide; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4-methylbenzenesulfonamide; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-3-methoxypropanamide; 4-methyl-N-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)benzenesulfonamide; N-((6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)methyl)-4-methylbenzenesulfonamide; 6-chloro-3-(1-(methylsulfonyl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-4-phenylquinolin-2(1H)-one; 6-chloro-3-(6-oxo-4-propyl-1,6-dihydropyrimidin-2-ylthio)-4-phenylquinolin-2(1H)-one; 6-chloro-3-(5-methoxy-1H-benzo[d]imidazol-2-ylthio)-4-phenylquinolin-2(1H)-one; 3-(5-benzyl-6-methyl-4-oxo-4,5-dihydropyrimidin-2-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; ethyl 2-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)acetate; 4-methyl-N-((6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)methyl)benzenesulfonamide; 6-chloro-4-phenyl-3-(phenylsulfonyl)quinolin-2(1H)-one; N-(6-bromo-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-2-(diethylamino)acetamide; 2-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)acetic acid; 6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl morpholine-4-carbodithioate; 6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl diethylcarbamodithioate; 6-chloro-3-(1-methyl-1H-imidazol-2-ylthio)-4-phenylquinolin-2(1H)-one; 3-(benzo[d]thiazol-2-ylthio)-7-chloro-4-phenylquinolin-2(1H)-one; 3-(5-amino-1,3,4-thiadiazol-2-ylthio)-7-chloro-4-phenylquinolin-2(1H)-one; 7-chloro-3-(3-(methylthio)-1,2,4-thiadiazol-5-ylthio)-4-phenylquinolin-2(1H)-one; 1-(6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-N-(3-(diethylamino)propyl)piperidine-3-carboxamide; 3-(6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide; 3-acetyl-6-bromo-4-phenylquinolin-2(1H)-one; 6-chloro-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)-4-phenylquinolin-2(1H)-one; 6-chloro-4-phenyl-3-(4-propoxypyrimidin-2-ylthio)quinolin-2(1H)-one; 3-(4-amino-5-p-tolyl-4H-1,2,4-triazol-3-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; 3-(4-amino-6-oxo-1,6-dihydropyrimidin-2-ylthio)-6-chloro-4-phenylquinolin-2(1H)-one; 6-chloro-3-(1-methyl-1H-tetrazol-5-ylthio)-4-phenylquinolin-2(1H)-one; 1-(6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)quinoxalin-2(1H)-one; 3-(4-amino-6-oxo-1,6-dihydropyrimidin-2-ylthio)-4-phenylquinolin-2(1H)-one; 5-(2-methoxybenzyl)-5-methyl-3-(2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)imidazolidine-2,4-dione; 6-bromo-4-phenyl-3-(2,2,2-trifluoroacetyl)quinolin-2(1H)-one; 4-phenyl-3-(quinazolin-4-yloxy)quinolin-2(1H)-one; 3-(4-methyl-5-(trifluoromethyl)-4H-1,2,4-triazol-3-ylthio)-4-phenylquinolin-2(1H)-one; 3-(3-fluorophenoxy)-4-phenylquinolin-2(1H)-one; 3-(5-(4-fluorophenyl)-2H-tetrazol-2-yl)-4-phenylquinolin-2(1H)-one; 2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-ethylacetamide; tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; 2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide. N1,N3-bis(4-bromophenyl)malonamide; N1,N3-bis(4-(3,5-dimethylisoxazol-4-yl)phenyl)malonamide; 6-(3,5-dimethylisoxazol-4-yl)-4-hydroxyquinolin-2(1H)-one; 4-chloro-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 4-(2-chlorobenzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one; 6-(3,5-dimethylisoxazol-4-yl)-4-morpholinoquinolin-2(1H)-one; 6-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-1-yl)quinolin-2(1H)-one; or 4-(benzylamino)-1-(benzylsulfonyl)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one.
(34) The compounds as provided herein may be used in the treatment of a variety of disorders and conditions and, as such, may be used in combination with a variety of other suitable therapeutic agents useful in the treatment or prophylaxis of those disorders or conditions. Thus, one embodiment of the present invention includes the administration of the compound of the present invention in combination with other therapeutic compounds. Such a combination of pharmaceutically active agents may be administered together or separately and, when administered separately, administration may occur simultaneously or sequentially, in any order. The amounts of the compounds or agents and the relative timings of administration will be selected in order to achieve the desired therapeutic effect. The administration in combination of a compound of the present invention with other treatment agents may be in combination by administration concomitantly in: (1) a unitary pharmaceutical composition including both compounds; or (2) separate pharmaceutical compositions each including one of the compounds. Alternatively, the combination may be administered separately in a sequential manner wherein one treatment agent is administered first and the other second. Such sequential administration may be close in time or remote in time.
(35) Another aspect of the present invention includes combination therapy comprising administering to the subject a therapeutically or prophylactically effective amount of the compound of the present invention and one or more other therapy including chemotherapy, radiation therapy, gene therapy, or immunotherapy.
(36) The compounds of the present invention can be used for the prevention or treatment of various conditions or disorders mediated by inhibiting bromodomain-containing proteins from binding acetylated proteins. The compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of various types of cancer, inflammation, obesity, metabolic, cardiovascular, neurodegenerative, psychiatric and infectious diseases. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis and viral infections. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of a variety of chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis, alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, atherosclerosis, depression, retinitis, uveitis, scleritis, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes and acute rejection of transplanted organs. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of a wide variety of acute inflammatory conditions such as acute gout, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis, vasculitis with organ involvement and acute rejection of transplanted organs. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of diseases or conditions which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria and SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex and coronavirus. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of conditions associated with ischaemia-reperfusion injury such as myocardial infarction, cerebro-vascular ischaemia (stroke), acute coronary syndromes, renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardio-pulmonary bypass procedures, pulmonary, renal, hepatic, gastro-intestinal or peripheral limb embolism. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of disorders of lipid metabolism via the regulation of APO-A1 such as hypercholesterolemia, atherosclerosis and Alzheimer's disease. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma and cardiac fibrosis. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of viral infections such as herpes virus, human papilloma virus, adenovirus and poxvirus and other DNA viruses. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of diseases associated with systemic inflammatory response syndrome include sepsis, burns, pancreatitis, major trauma, haemorrhage and ischaemia. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of SIRS, the onset of shock, multi-organ dysfunction syndrome, which includes the onset of acute lung injury, ARDS, acute renal, hepatic, cardiac and gastro-intestinal injury and mortality. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of sepsis, sepsis syndrome, septic shock and endotoxaemia, acute or chronic pancreatitis, herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus, cervical neoplasia, adenovirus infections, including acute respiratory disease, poxvirus infections such as cowpox and smallpox and African swine fever virus and for the treatment of Human papilloma virus infections of skin or cervical epithelia. According to one embodiment, the compounds and their pharmaceutical compositions are particularly useful in the treatment or prevention of various forms of cancer, leukemias and lymphomas including acute myeloid luekiemia, Burkitt's lymphoma, multiple myeloma, T-cell lymphoblastic leukemia and other hemotological cancers that involve translocations of mixed-lineage leukemia gene (MLL); solid tumors such as hepatocellular carcinoma, glioblastoma, neuroblastoma, NUT midline carcinoma, sarcoma, breast, colorectal, lung, pancreatic and prostate cancer; osteoarthritis and rheumatoid arthritis; Alzheimer's disease; and HIV infection.
(37) The present invention also provides a method for the synthesis of compounds useful as intermediates in the preparation of compounds of the present invention along with methods for their preparation. The compounds can be prepared according to the methods described below using readily available starting materials and reagents. In these reactions, variants may be employed which are themselves known to those of ordinary skill in this art but are not described in detail here. Those skilled in the art of organic synthesis will appreciate that there exist multiple means of producing compounds of the present invention. Illustrative synthetic methods, including those directed to specific, selected compounds noted in Tables 1, 2, 3, 4, 5, and 6 are set forth herein.
(38) TABLE-US-00001 TABLE 1 Compound Structure 1.
(39) TABLE-US-00002 TABLE 2 Compounds of Formula IA Formula 1A
(40) TABLE-US-00003 TABLE 3 Formula 1B
(41) TABLE-US-00004 TABLE 4 Formula 1C
(42) TABLE-US-00005 TABLE 5 Forumla 1C
(43) TABLE-US-00006 TABLE 6 Formula 1D
Example 1 (Compounds 21-41 of Table 1)
(44) Compounds 21-41 set forth in Table 1 may be prepared according the synthetic scheme set forth below. Those skilled in the art of organic synthesis will recognize that other substituents may be introduced to the three position (e.g., (NHRR)) and four position according to the scheme.
(45) ##STR00616##
Example 2: Synthetic SchemeFormula 1A
(46) Compounds of Formula 1A may be prepared according to the synthetic scheme set forth below.
(47) ##STR00617## ##STR00618##
(48) Benzotriazole 1 can be reacted with 2-oxoacetic acid and Cbz-NH2 to get compound 2 which can be coupled with an aniline derivative 3 in presence of a coupling reagent to obtain compound 4. Compound 5 can be obtained by treatment of compound 4 with ammonia or ammonia equivalent. An alkylation of compound 5 will provide compound 6 and subsequent treatment of compound 6 with Lawesson reagent can provide compound 7. Reaction of compound 7 with hydrazine can provide the hydrazine derivative 8 which can be treated with desired carboxylic acid to get the compound 9. Deprotection of the Cbz group followed by appropriate derivatization will provide the targeted compound of the Formula 1A.
Example 3Synthetic Scheme
(49) The targeted compound of Formula 1A can be prepared by reacting compounds 1, 3, 5, 7 with appropriate side chains having a reacting group as shown below.
(50) ##STR00619## ##STR00620##
Example 4Synthetic Scheme
(51) The compound 1 can be prepared according to the scheme of Example 2. The treatment of compound 1 with 1,1,1-triethoxyethane will give compound 2 which can be further reacted with carbon monoxide using the palladium catalyst to obtain a carboxylic acid ester derivative 3. The coupling of compound 4 with 2-aminoethanol will provide desired compound 5 of Formula 1A.
(52) ##STR00621##
Example 5Synthetic Scheme
(53) Benzotriazole 1 can be reacted with 2-oxoacetic acid and Cbz-NH2 to get compound 2 which can be coupled with an aniline derivative 3 in presence of a coupling reagent 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide to obtain compound 4. Compound 5 can be obtained by treatment of compound 4 with ammonia in methanol or ammonia acetate. Treatment of compound 4 with Lawesson reagent can provide compound 5 and subsequent reaction of compound 7 with hydrazine can provide the hydrazine derivative 6 which can be treated with 2-(3,5-dimethylisoxazol-4-yl)acetic acid to get the compound 7. The cyclization of compound 7 in presence of mixture of acetic acid and acetic anhydride will provide compound 8 of Formula 1A.
(54) ##STR00622## ##STR00623##
Example 6Synthetic Scheme
(55) The deprotection of the silyl protecting group using TBAF will provide the free phenolic derivative which then can be treated with 2-chloroacetamide in presence of triethylamine to provide compound 3 of the Formula 1A.
(56) Additionally compound 2 also can be reacted with the (2-bromoethoxy)(tert-butyl)dimethylsilane in presence of triethylamine to get compound 5. The deprotection of the silyl protecting group will provide the desired compound 6 of Formula 1A.
(57) ##STR00624##
Example 7Synthetic SchemeFormula 1B
(58) Compounds of Formula 1B may be prepared according to the synthetic scheme set forth below.
(59) The substituted isoxazole boronic acid can be reacted with 3-iodo or 3-bromo aniline derivatives 2 using Suzuki coupling conditions to give the corresponding amino compounds. Compound 2 may be reacted with diethyl ethoxymethylenemalonate at appropriate temperature with heating conditions to get compound 4. Hydrolysis of compound 4 will provide compound 5 and subsequent decaboxylation will yield compound 6. The nitration of compound 6 will provide corresponding nitro derivative 7 that can be treated with POCl3 to get the chloro compound 8. The chloro compound then can be treated with appropriate amine to produce compound 9 and subsequent protection of the amine will provide compound 10. The alkylation of compound 10 with halide or reductive alkylation using aldehyde will provide compound 11. The deprotection of the protecting group on compound 10 and then cyclization using di-tert-butyl dicarbonate will produce desired compounds of Formula 1B.
(60) ##STR00625## ##STR00626## ##STR00627##
Example 8Synthetic Scheme
(61) The deprotection of compound 1 will provide compound 2 which can be then reacted with an appropriate side chain with to yield desired compound 3 of Formula 1B.
(62) ##STR00628##
Example 9Synthetic SchemeFormula 1C
(63) Compounds of Formula 1C may be prepared according to the synthetic scheme set forth below.
(64) The reaction of 4-hydroxyquinolin-2(1H)-one derivative 1 with POCl3 will produce the corresponding dichloro compound 2 and subsequent treatment of compound 2 with aqueous HCl generate compound 3. The alkylation of compound 3 with an appropriate amine will produce the corresponding amino derivative 4 which can be further derivatized to yield compounds of Formula 1C.
(65) ##STR00629##
Example 10Synthetic Scheme
(66) The reaction of 4-bromoaniline with diethyl malonate under heating conditions will produce compound 3 which can be then treated with (3,5-dimethylisoxazol-4-yl)boronic acid under Suzuki reaction conditions to yield compound 4. The compound 4 can be cyclized to produce 6-(3,5-dimethylisoxazol-4-yl)-4-hydroxyquinolin-2(1H)-one by heating with polyphosphoric acid. Further reaction of 5 with POCl3 will yield the dichloro compound 6 and treatment of 6 with aqueous HCl will give compound 7. The reaction of compound 7 with benzylamine will provide the desired compound 8 of the Formula 1C.
(67) ##STR00630## ##STR00631##
Example 11Synthetic SchemeFormula 1D
(68) Compounds of Formula 1D may be prepared according to the synthetic scheme set forth below.
(69) The reduction of a substituted nitrobenzene derivative may give the corresponding amino compounds. Compound 2 may be then reacted with diethyl ethoxymethylenemalonate at appropriate temperature with heating conditions to get compound 3. Hydrolysis of compound 3 will provide compound 4 and subsequent decaboxylation will yield compound 5. The reaction of compound 7 with POCl3 may yield the chloro compound 6. The chloro compound then can be treated with appropriate amine to produce compound 7 and subsequent derivatization of 7 can produce compound 8. Deprotection of the compound 8 followed by an appropriate derivatization will provide compound 10 of Formula 1D.
(70) ##STR00632## ##STR00633##
Example 12Synthetic Scheme
(71) 2-Iodo-4-nitrophenol can be reacted with p-methoxybenzoyl chloride to produce PMB protected derivative 2 which than can be treated with (3,5-dimethylisoxazol-4-yl)boronic acid under Suzuki reaction conditions to yield compound 3. After reduction of nitro compound 3 to amino derivative 4, it can be treated with diethyl ethoxymethylenemalonate at appropriate temperature with heating conditions to get compound 5. Hydrolysis of the ester derivative 5 will provide compound 6 and subsequent decaboxylation will yield compound 7. The compound 7 can be treated with POCl3 to get the chloro compound 8. The chloro compound then can be treated with pyridin-2-ylmethanamine to produce compound 9 and subsequent acylation with acetyl chloride of the amine will provide compound 10. The deprotection of the protecting group of phenol of compound 10 will provide the phenolic compound 11 which can be further derivatized using appropriate alkyl halides to produce corresponding compounds 12 and 13 of Formula 1D.
(72) ##STR00634## ##STR00635## ##STR00636##
Example 13: 6-chloro-3-(3-(2-methoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one (Compound 5Table 1)
(73) (2-amino-5-chlorophenyl)(phenyl)methanone (10 g) was treated with EAA at 180 C. in a sealed tube for five hours to yield 3-acetyl-6-chloro-4-phenylquinolin-2(1H)-one (4.5 g). A portion of the 3-acetyl-6-chloro-4-phenylquinolin-2(1H)-one (200 mg) was subsequently treated with 2-methoxybenzaldehyde and NaOH (25 equiv) in water and ethanol at room temperature for 16 hours to yield 6-chloro-3-(3-(2-methoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one (60 mg)(LCMS (m/z)=415.10).
Example 14: 6-chloro-3-(3-(3,4-dimethoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one (Compound 6Table 1)
(74) 3-acetyl-6-chloro-4-phenylquinolin-2(1H)-one (200 mg)(see Example 1) was treated with 3,4-dimethoxybenzaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-chloro-3-(3-(3,4-dimethoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one (55 mg) (LCMS (m/z)=445.11).
Example 15: 6-chloro-4-phenyl-3-(3-(thiophen-2-yl)acryloyl)quinolin-2(1H)-one (Compound 7Table 1)
(75) 3-acetyl-6-chloro-4-phenylquinolin-2(1H)-one (200 mg)(see Example 1) was treated with thiophene-2-carbaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-chloro-4-phenyl-3-(3-(thiophen-2-yl)acryloyl)quinolin-2(1H)-one (55 mg) (LCMS (m/z) 391.04).
Example 16: 6-chloro-3-(3-(4-(dimethylamino)phenyl)acryloyl)-4-phenylquinolin-2(1H)-one (Compound 8Table 1)
(76) 3-acetyl-6-chloro-4-phenylquinolin-2(1H)-one (200 mg) was treated with 4-(dimethylamino) benzaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-chloro-3-(3-(4-(dimethylamino)phenyl)acryloyl)-4-phenylquinolin-2(1H)-one (40 mg) (LCMS (m/z)=428.13).
Example 17: 6-bromo-3-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acryloyl)-4-phenylquinolin-2(1H)-one (Compound 9Table 1)
(77) (2-aminophenyl)(phenyl)methanone (500 mg) was reacted with KBr, ammonium molbedate, and sodium per borate in AcOH at 0 C. for 16 hours to yield (2-amino-5-bromophenyl)(phenyl)methanone (80 mg). A portion of the (2-amino-5-bromophenyl)(phenyl)methanone (200 mg) was treated with EAA at 180 C. in a sealed tube for 10 hours and subsequently washed to yield 3-acetyl-6-bromo-4-phenylquinolin-2(1H)-one (80 mg). A portion of the 3-acetyl-6-bromo-4-phenylquinolin-2(1H)-one (300 mg) was treated with 2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-bromo-3-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acryloyl)-4-phenylquinolin-2(1H)-one (120 mg).
Example 18: 6-bromo-3-(3-(2,5-dimethoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one (Compound 10Table 1)
(78) 3-acetyl-6-bromo-4-phenylquinolin-2(1H)-one (200 mg)(see Example 5) was treated with 2,5-dimethoxybenzaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-bromo-3-(3-(2,5-dimethoxyphenyl)acryloyl)-4-phenylquinolin-2(1H)-one (55 mg) (LCMS (m/z)=489.06).
Example 19: 6-chloro-3-cinnamoyl-4-(pyridin-4-yl)quinolin-2(1H)-one (Compound 11Table 1)
(79) 4-chloroaniline (2 g) was treated with isonicotinonitrile in the presence of BCl.sub.3 and AlCl.sub.3 in DCM at 0 C. to 45 C. for 16 hours to yield (2-amino-5-chlorophenyl)(pyridin-4-yl)methanone (300 mg). A portion of the (2-amino-5-chlorophenyl)(pyridin-4-yl)methanone (200 mg) was treated with EAA at 180 C. in a sealed tube for 6 hours to yield 3-acetyl-6-chloro-4-(pyridin-4-yl)quinolin-2(1H)-one (60 mg). A portion of the 3-acetyl-6-chloro-4-(pyridin-4-yl)quinolin-2(1H)-one (200 mg) was treated with benzaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-chloro-3-cinnamoyl-4-(pyridin-4-yl)quinolin-2(1H)-one (55 mg) (LCMS (m/z)=386.08).
Example 20: 6-chloro-4-(pyridin-3-yl)-3-(3-o-tolylacryloyl)quinolin-2(1H)-one (Compound 12Table 1)
(80) 3-acetyl-6-chloro-4-(pyridin-4-yl)quinolin-2(1H)-one (200 mg)(see Example 7) was treated with 2-methylbenzaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-chloro-4-(pyridin-3-yl)-3-(3-o-tolylacryloyl)quinolin-2(1H)-one (100 mg).
Example 21: 6-chloro-N-(2-methylbenzyl)-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxamide (Compound 13Table 1)
(81) (2-amino-5-chlorophenyl)(phenyl)methanone (1 g) was treated with diethyl malonate and piperidine at 180 C. in a sealed tube for six hours to yield ethyl 6-chloro-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxylate (400 mg). A portion of the obtained ethyl 6-chloro-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxylate (380 mg) was treated with aqueous NaOH at room temperature for four hours. The resulting mixture was then heated to 100 C. for twelve hours to yield 6-chloro-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxylic acid (200 mg). The obtained 6-chloro-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxylic acid (200 mg) was reacted with COCl.sub.2 in a CCl.sub.4 reflux for three hours. The reaction mixture was concentrated and dissolved in acetone and added to a solution of o-tolylmethanamine and TEA in acetone at 0 C. and stirred at room temperature for three hours to yield 6-chloro-N-(2-methylbenzyl)-2-oxo-4-phenyl-1,2-dihydroquinoline-3-carboxamide (60 mg) (LCMS (m/z)=402.11).
Example 22: 6-chloro-3-cinnamoyl-4-phenyl-1,8-naphthyridin-2(1H)-one (Compound 14Table 1)
(82) 5-chloropyridin-2-amine (20 g) was treated with pivaloyl chloride/TEA in DCM at 00 C. for two hours to yield N-(5-chloropyridin-2-yl)pivalamide (15 g). A portion of the obtained N-(5-chloropyridin-2-yl)pivalamide (10 g) was treated with t-butyl lithium, N-methoxy-N-methylbenzamide in THF at 78 C. for three hours. The reaction mixture was allowed to warm up to room temperature, stirred for three hours and crystallized to yield N-(3-benzoyl-5-chloropyridin-2-yl)pivalamide (4.5 g). The obtained N-(3-benzoyl-5-chloropyridin-2-yl)pivalamide (4.5 g) was reacted with 3N HCl in 1, 4 dioxane at reflux temperature for five hours to yield (2-amino-5-chloropyridin-3-yl)(phenyl)methanone (2.5 g). A portion of the (2-amino-5-chloropyridin-3-yl)(phenyl)methanone (2.0 g) was treated with EAA at 170 C. overnight to yield 3-acetyl-6-chloro-4-phenyl-1,8-naphthyridin-2(1H)-one (400 mg). A portion of the obtained 3-acetyl-6-chloro-4-phenyl-1,8-naphthyridin-2(1H)-one (350 mg) was reacted with benzaldehyde and aqueous NaOH in ethanol at room temperature for eight hours to yield 6-chloro-3-cinnamoyl-4-phenyl-1,8-naphthyridin-2(1H)-one (100 mg).
Example 23: 6-chloro-3-(3-(2-chloro-6-fluorophenyl)acryloyl)-4-(pyridin-4-yl)quinolin-2(1H)-one (Compound 15Table 1)
(83) 3-acetyl-6-chloro-4-(pyridin-4-yl)quinolin-2(1H)-one (200 mg)(see Example 7) was treated with 3,4-dimethoxybenzaldehyde and NaOH in water and ethanol at room temperature for 16 hours to yield 6-chloro-3-(3-(2-chloro-6-fluorophenyl)acryloyl)-4-(pyridin-4-yl)quinolin-2(1H)-one (100 mg) (LCMS (m/z)=439.3).
Example 24: 6-chloro-3-(3-(3-fluoro-5-methylpyridin-4-yl)acryloyl)-4-(pyridin-3-yl)quinolin-2(1H)-one (Compound 16Table 1)
(84) 3-fluoro-5-methylpyridine (1.6 g) was treated with freshly prepared LDA and methyl formate at 78 C. for five hours to yield 3-fluoro-5-methylisonicotinaldehyde (700 mg). 3-acetyl-6-chloro-4-(pyridin-3-yl)quinolin-2(1H)-one (250 mg) was reacted with 3-fluoro-5-methylisonicotinaldehyde (3 equivalents) in aqueous NaOH and ethanol at room temperature for 14 hours to yield 6-chloro-3-(3-(3-fluoro-5-methylpyridin-4-yl)acryloyl)-4-(pyridin-3-yl)quinolin-2(1H)-one (50 mg) (LCMS (m/z)=420.1).
Example 25: 6-chloro-3-(3-(2-chloro-6-fluorophenyl)but-2-enoyl)-4-phenylquinolin-2(1H)-one (Compound 19Table 1)
(85) (2-amino-5-chlorophenyl)(phenyl)methanone (2 g) was converted to 3-acetyl-6-chloro-4-phenylquinolin-2(1H)-one (800 mg) which, in turn, was converted to 6-chloro-3-(3-(2-chloro-6-fluorophenyl)but-2-enoyl)-4-phenylquinolin-2(1H)-one (225 mg).
Example 26: 3-cinnamoyl-6-(3,5-dimethylisoxazol-4-yl)-4-(pyridin-3-yl)quinolin-2(1H)-one (Compound 20Table 1)
(86) 4-bromoaniline (40 mg) was treated with isonicotinonitrile in the presence of BCl.sub.3/AlCl.sub.3 in DCM at 0 C. to 45 C. for 16 hours to yield (2-amino-5-bromophenyl)(pyridin-3-yl)methanone (7 g). A portion of the obtained (2-amino-5-bromophenyl)(pyridin-3-yl)methanone (100 mg) was reacted with EAA in ethanol at 180 C. in a sealed tube for 12 hours to yield 3-acetyl-6-bromo-4-(pyridin-3-yl)quinolin-2(1H)-one (20 mg). The aforementioned reaction was repeated to yield additional 3-acetyl-6-bromo-4-(pyridin-3-yl)quinolin-2(1H)-one. A portion of the obtained 3-acetyl-6-bromo-4-(pyridin-3-yl)quinolin-2(1H)-one (400 mg) was treated with benzaldehyde and NaOH (aqueous) in ethanol at room temperature for 16 hours to yield 6-bromo-3-cinnamoyl-4-(pyridin-3-yl)quinolin-2(1H)-one (130 mg). A portion of the 6-bromo-3-cinnamoyl-4-(pyridin-3-yl)quinolin-2(1H)-one 940 mg) was treated with 3,5-dimethylisoxazol-4-ylboronic acid, Pd(dppf).sub.2Cl.sub.2, N-methyldicyclohexyl amine, NaOH, in THF at 70 C. for 16 hours to yield 3-cinnamoyl-6-(3,5-dimethylisoxazol-4-yl)-4-(pyridin-3-yl)quinolin-2(1H)-one (6 mg) (LCMS (m/z)=448.04).
Example 27: N1,N3-bis(4-bromophenyl)malonamide
(87) ##STR00637##
(88) 4-Bromoaniline (20 mmol) and diethylmalonate (10 mmol) was heated to 150 C. for 20 hr. Reaction was cooled and diluted with ethanol and filtered to give the desired product as a grey solid (1.10 g). .sub.H (DMSO-d.sub.6, 400 MHz) 10.32 (s, 2H, 2NH.sub.2), 7.58 (d, 4H, J=9.6, Ar), 7.51 (d, 4H, J=9.6, Ar), 3.48 (s, 2H, CH.sub.2); .sub.C (DMSO-d.sub.6, 100 MHz) 165.9, 138.7, 132.0, 121.4, 115.4, 46.4.
Example 28: N1,N3-bis(4-(3,5-dimethylisoxazol-4-yl)phenyl)malonamide
(89) ##STR00638##
(90) N1,N3-bis(4-bromophenyl)malonamide (0.50 mmol) and isoxazole boronic acid (1.08 mmol) were dissolved in toluene/EtOH (8 mL/8:2). 2M Na.sub.2CO.sub.3 (735 uL) and palladium tetrakis (113 mg) were added and heated to 90 C. for 5 hr. Reaction was cooled, partitioned between EtOAc and H.sub.2O. The organic portion was washed with H.sub.2O, sat. NaCl and dried over Na.sub.2SO.sub.4. Column chromatography gave the desired product as a yellow solid (117 mg). .sub.H (CDCl.sub.3, 400 MHz) 9.25 (s, 2H, 2NH2), 7.66 (d, 4H, J=8.6, Ar), 7.23 (d, 4H, J=8.6, Ar), 3.61 (s, 2H, CH.sub.2), 2.39 (s, 3H, Me), 2.56 (s, 3H, Me).
Example 29: 6-(3,5-dimethylisoxazol-4-yl)-4-hydroxyquinolin-2(1H)-one
(91) ##STR00639##
(92) N1,N3-bis(4-(3,5-dimethylisoxazol-4-yl)phenyl)malonamide (117 mg) was treated with polyphosphoric acid (5 eq. by weight) and heated to 140 C. for 5 hr. Reaction was cooled, diluted with H.sub.2O and filtered to give the desired product as a white solid (65 mg). .sub.H (DMSO-d.sub.6, 400 MHz) 11.43 (br s, 1H, OH), 11.30 (s, 1H, NH), 7.70 (s, 1H, Ar), 7.51 (dd, 1H, J=8.4, 1.6, Ar), 7.35 (d, 1H, J=8.4, Ar), 5.77 (s, 1H, CH), 2.40 (s, 3H, Me), 2.22 (s, 3H, Me).
Example 30: 4-chloro-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one
(93) ##STR00640##
(94) 6-(3,5-dimethylisoxazol-4-yl)-4-hydroxyquinolin-2(1H)-one (40 mg) was treated with NEt.sub.3 (65 uL), POCl.sub.3 (0.5 mL) and heated to 65 C. for 3 hr. Reaction was cooled, partitioned between EtOAc and H.sub.2O. The organic portion was washed with H.sub.2O, sat. NaCl and dried over Na.sub.2SO.sub.4. Column chromatography gave the desired intermediate as a brown solid. The solid was dissolved in dioxane (2 mL) and 6M HCl (2 mL) was added and refluxed for 4 hr. Reaction was cooled, diluted with H.sub.2O, neutralized to pH 9 with solid K.sub.2CO.sub.3 and filtered to give the desired product as a cream solid (34 mg). .sub.H (DMSO-d.sub.6, 400 MHz) 12.15 (s, 1H, NH), 7.78 (s, 1H, Ar), 7.67 (d, 1H, J=8.4, Ar), 7.48 (d, 1H, J=8.4, Ar), 6.89 (s, 1H, CH), 2.42 (s, 3H, Me), 2.24 (s, 3H, Me).
Example 31: 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one
(95) ##STR00641##
(96) 4-chloro-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one was heated to 120 C. in a 1:1 mixture of DMSO and benzylamine. Reaction was cooled, partitioned between EtOAc and H.sub.2O. The organic portion was washed with H.sub.2O, sat. NaCl and dried over Na.sub.2SO.sub.4. Column chromatography gave the desired product as a cream solid (10 mg) after lyophilization. .sub.H (DMSO-d.sub.6, 400 MHz) 10.86 (s, 1H, NH), 7.99 (s, 1H, Ar), 7.71 (t, 1H, J=5.2, NH), 7.56 (d, 1H, J=8.8, Ar), 7.40-7.21 (m, 6H, Ar), 5.16 (s, 1H, CH), 4.46 (d, 2H, J=5.2, CH.sub.2), 2.42 (s, 3H, Me), 2.26 (s, 3H, Me).
Example 32: 4-(2-chlorobenzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one
(97) ##STR00642##
(98) A similar procedure as set forth in Example 16 gave the desired product as a cream solid (15 mg). .sub.H (DMSO-d.sub.6, 400 MHz) 10.94 (s, 1H, NH), 8.01 (s, 1H, Ar), 7.18 (t, 1H, J=5.6, NH), 7.53-7.47 (m, 2H, Ar), 7.39-7.30 (m, 4H, Ar), 5.06 (s, 1H, CH), 4.52 (d, 2H, J=5.6, CH.sub.2), 2.44 (s, 3H, Me), 2.28 (s, 3H, Me).
Example 33: 6-(3,5-dimethylisoxazol-4-yl)-4-morpholinoquinolin-2(1H)-one
(99) ##STR00643##
(100) A similar procedure as set forth in Example 16 gave the desired product as a white solid (12 mg). .sub.H (DMSO-de, 400 MHz) 11.51 (s, 1H, NH), 7.60 (s, 1H, Ar), 7.54 (d, 1H, J=8.8, Ar), 7.40 (d, 1H, J=8.8, Ar), 5.94 (s, 1H, CH), 3.88-3.80 (m, 4H, Ar), 3.12-3.05 (m, 4H, Ar), 2.43 (s, 3H, Me), 2.25 (s, 3H, Me).
Example 34: 6-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-1-yl)quinolin-2(1H)-one
(101) ##STR00644##
(102) A similar procedure as set forth in Example 16 gave the desired product as a cream solid (6 mg). .sub.H (DMSO-d.sub.6, 400 MHz) .sub.H (DMSO-d.sub.6, 400 MHz) 11.43 (s, 1H, NH), 7.55-7.50 (m, 2H, Ar), 7.38 (d, 1H, J=8.4, CH.sub.2), 5.87 (s, 1H, CH), 3.20-3.01 (m, 4H, Ar), 2.44 (s, 3H, Me), 2.26 (s, 3H, Me), 1.79-1.70 (m, 4H, Ar), 1.67-1.58 (m, 2H, Ar).
Biological Assays
Example 35: In Vitro Cell Viability
(103) MV4-11 acute myeloid leukemia cells (American Type Culture Collection, Manassas, Va.) were added to 96-well clear bottom assay plates containing RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at approximately 30,000 cells/well and incubated for 24 hours at 37 C. with 5% CO.sub.2 and 95% humidity. Control wells containing no cells were included to measure background fluorescence signal. Test compounds were dissolved at 10-20 M and diluted two-fold in DMSO to produce a working stock of compound solutions. Aliquots of the working stock solutions were subsequently diluted 100-fold in basal RPMI-1640 medium which was then further diluted 10-fold to the assay plate containing the cells to provide 10 test concentrations ranging from 0.04 M-20 M. Following a 72-hour incubation period, viability of the cells was determined by the alamarBlue assay (Life Technologies, Carlsbad, Calif.) following the manufacturer's protocol. Prior to generation of dose response curves, the data were background subtracted using the no cell control values (mean+/standard deviation) and fluorescence values versus Log.sub.10 concentration of test compounds were plotted using GraphPad Prism. The resulting sigmoidal curve was then fit to the graph and IC.sub.50 values were calculated using a 4 parameter (4PL) algorithm using the following equation: 4(PL) F(x)=(AD)/(1+(x/c).sup.B+D, where A=lower asymptote (baseline response), D=upper asymptote (maximum response), C=drug concentration that provokes a response halfway between A and D, B=slope of the curve. The results for selected compounds are set forth in Table 7.
(104) TABLE-US-00007 TABLE 7 Compound In Vitro Cell Viability (IC.sub.50) (Table 1) MV4-11 Cells (AML) MM1.S Cells (Multiple Myeloma) 1 0.11 M 5 1.49 M 2.53 M 6 3.57 M 31.9 M 7 2.3 M 8 10.31 M 9 5.52 M 10 1.75 M 3 M 11 0.97 M 4.21 M 12 1.04 M 2.44 M 13 4.73 M 3.1 M 14 0.71 M 14.1 M 15 1.18 M 16 0.4 M 21 8.6 M 22 1.8 M 81 3 M 127 5.45 M 147 0.22 M 148 0.25 M
Example 36: Gene Expression Change of MYC Oncogene
(105) Approximately 110.sup.6 MV4-11 were exposed to either DMSO as vehicle control or test compounds at 10 M for one hour in RPMI medium supplemented with 10% FBS. Total RNA was prepared from the exposed cells using RNeasy Mini Kit (Qiagen, Venlo, Netherlands) and reverse transcription was performed with qScript cDNA SuperMix (Quanta BioSciences, Gaithersburg, Md.) following manufacturers' protocols to yield complementary DNA (cDNA). Quantitative polymerase chain reaction was performed on MX3000 7500 Real-Time PCR system (Agilent Technologies, Santa Clara, Calif.) using cDNA derived from approximately 50 ng of total RNA and PerfeCTa SYBR Green FastMix (Quanta BioSciences) with a thermal profile consisting of denaturation at 95 C. for 10 min followed by 40 cycles of denaturation at 95 C. for 10 seconds and annealing/elongation at 60 C. for 30 seconds. The expression of MYC gene was detected by using the forward primer 5-CTG GTG CTC CAT GAG GAG A-3 and reverse primer 5-CCT GCC TCT TTT CCA CAG AA-3 while the expression of GAPDH gene was measured with GAPDH PerfeCTa Reference Gene Assay primers (Quanta BioSciences). Critical threshold (CT) values were obtained with MX Pro software (Agilent Technologies) and the gene expression fold changes were calculated for both MYC and GAPDH genes compared to vehicle control assuming that 1 CT value change corresponds to two-fold difference in gene expressions. MYC gene expression fold changes were then divided by the values for GAPDH gene in order to account for sample-to-sample loading differences. The results for selected compounds are set forth in Table 8.
(106) TABLE-US-00008 TABLE 8 Gene Expression Change of MYC Oncogene (in vitro) Compound (Table 1) MV4-11 Cells (AML) - Fold Change 1 1.4/1.3 2 1.4 3 1.4 4 1.4 5 1.6 6 1.7 7 1.3 8 1.3 10 1.3 11 3.0 12 2.8 13 1.3 14 3.0 15 2.3 21 1.2 22 1.1 23 1.0 24 1.2 70 1.2 71 1.1 72 1.3 73 1.5 74 1.0 75 1.5 76 1.3 77 1.2 78 1.5 79 1.1 80 1.3 81 1.9 82 1.2 90 3.0 91 1.3 92 1.5 93 1.6 94 1.2 95 1.4 96 1.3 97 1.5 98 1.5 99 1.4 100 1.0 101 1.5 102 1.1 143 1.2 144 1.6/1.7 145 1.6/1.6
Example 37: Amplified Luminescent Proximity Homogeneous Assay (ALPHA)
(107) The interactions between test compounds and BRD4 protein containing both bromodomain 1 and bromodomain 2 were measured with human BRD4 protein with N-terminal His tag (BPS Bioscience, San Diego, Calif.) using AlphaScreen assay at room temperature. A 9 l reaction mixture in BRD Assay Buffer (BPS Bioscience) containing 25 nM BRD4 and test compounds at various concentrations were incubated for 30 minutes followed by additional 30-minute incubation with 1 l of 20 M histone H4 peptide (residue 1-21) in the presence of 5% DMSO. Test compounds (see Table 4) were assayed at 10 M or 31.6 M for screening purpose, while 8 different concentrations (10 nM-10 M) were used for IC.sub.50 measurements. After the incubation, 20 l of BRD Detection Buffer (BPS Bioscience) containing 10 g/ml Glutathione Acceptor beads and 10 g/ml Streptavidin Donor beads (PerkinElmer, Waltham, Mass.) was added and the mixture was incubated for 50 minutes in darkroom. Binding measurements were taken in duplicate at each concentration using EnSpire Alpha Multimode Plate Reader Model 2390 (PerkinElmer). The AlphaScreen data were analyzed using Graphpad Prism (La Jolla, Calif.). In the absence of the compound, the AlphaScreen signal (A.sub.t) in each data set was defined as 100% activity. In the absence of the histone H4 peptide ligand, the AlphaScreen signal (A.sub.b) in each data set was defined as 0% activity. The percent activity in the presence of each compound was calculated according to the following equation: % activity=[(AA.sub.b)/(A.sub.tA.sub.b)]100, where A=the AlphaScreen signal in the presence of compound; A.sub.b=the AlphaScreen signal in the absence of the histone peptide ligand; and A.sub.t=the AlphaScreen signal in the absence of the compound. The percent inhibition was calculated according to the following equation: % inhibition=100% activity.
(108) The inhibitory effects of select compounds from Table 1 are shown in Table 9.
(109) TABLE-US-00009 TABLE 9 BRD4-BD1-BD2 Compound (Table 1) IC.sub.50 % Inhibition 1 2.43 M 87% 83 442 nM 99% 84 372 nM 98% 85 876 nM 99% 86 670 nM 99% 87 139 nM 99% 88 864 nM 98% 89 586 nM 99% 90 11.2 M 62% 97 5.8 M 59% 98 6.7 M 64% 121 7.3 M 68% 122 26.8 M 65% 124 17.3 M 50% 126 23.6 M 50% 128 16.3 M 64% 132 3.7 M 92% 143 99% 144 0.049 M >90% 145 1.44 M 72%
Example 38: Amplified Luminescent Proximity Homogeneous Assay (ALPHA)
(110) Assays were performed by AlphaScreening technology using a recombinant BRD4-BD1-BD2 and BET Ligand. The AlphaScreening signal from the assay was correlated with the amount of BET Ligand binding to the bromodomain. The compounds were diluted in 50% DMSO and 1 l of the dilution was added to a 10 l reaction so that the final concentration of DMSO is 5% in all of reactions. All reactions were conducted at room temperature. The 9 l reaction mixture in BRD Assay Buffer contains 2.5 nM BRD4-BD1-BD2 and the indicated amount of the inhibitor, and the reaction mixture were incubated for 30 min followed by additional 30 min incubation after the addition of 1 l of BET Ligand (Table 2.3.1). For the negative control (blank), 1 l of the assay buffer was added instead of the BET Ligand. After the 30 min incubation with the BET Ligand, 20 l of BRD Detection buffer containing 10 g/ml Glutathione acceptor beads and 10 g/ml Streptavidin Donor beads was added and the final 30 l mixture was incubated for 50 min in a dark room.
(111) AlphaScreening signal was measured using EnSpire Alpha 2390 Multilabel reader (Perkin Elmer). Binding experiments were performed in duplicate at each concentration. The AlphaScreening data were analyzed using the computer software, Graphpad Prism. In the absence of the compound, the AlphaScreening signal (A.sub.t) in each data set was defined as 100% activity. In the absence of the BET Ligand, the AlphaScreening signal (A.sub.b) in each data set was defined as 0% activity. The percent activity in the presence of each compound was calculated according to the following equation: % activity=[(AA.sub.b)/(A.sub.tA.sub.b)]100, where A=the AlphaScreening signal in the presence of the compound, A.sub.b=the AlphaScreening signal in the absence of the BET Ligand, and A.sub.t=the AlphaScreening signal in the absence of the compound. The percent inhibition was calculated for certain compounds according to the following equation: % inhibition=100% activity.
(112) The inhibitory effects of select compounds are shown in Table 10.
(113) TABLE-US-00010 TABLE 10 % inhibition Compound Structure at 10 M
(114) The specific pharmacological responses observed may vary according to and depending on the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with practice of the present invention.
(115) Although specific embodiments of the present invention are herein illustrated and described in detail, the invention is not limited thereto. The above detailed descriptions are provided as exemplary of the present invention and should not be construed as constituting any limitation of the invention. Modifications will be obvious to those skilled in the art, and all modifications that do not depart from the spirit of the invention are intended to be included with the scope of the appended claims.